Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562180 | 0.86 | ALDH1A1 (0.69) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL24576223 | 0.86 | NPC1 (0.71) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL12133623 | 0.85 | KMT2A (0.76) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3450034 | 0.85 | TSHR (0.71) | SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL1695235 | 0.85 | NPC1 (0.66) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL2721206 | 0.85 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL15514376 | 0.85 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL4712377 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AMTNR1A | |
| SCHEMBL5902331 | 0.84 | NPC1 (0.65) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A | |
| SCHEMBL4588182 | 0.83 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1PKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980302-A | Piperazine-based agonists of LFA-1 and VLA-4 | 德克萨斯心脏研究所 | 2024-05-03 | — | — | CN | claimed |
| CN-111187176-B | Method for preparing N-vinyl amide compound under catalysis of copper salt | 浙江工业大学 | 2022-11-25 | — | — | CN | claimed |
| CN-111187176-A | Method for preparing N-vinyl amide compound under catalysis of copper salt | 浙江工业大学 | 2020-05-22 | — | — | CN | claimed |
| CN-107567445-A | It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor | 坎塞拉有限公司 | 2018-01-09 | — | — | CN | claimed |
| WO-2016124553-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2016-08-11 | — | — | WO | claimed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| EP-1624868-A1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | Pfizer Limited (GB) | 2006-02-15 | — | — | EP | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2004100950-A1 | ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-25 | — | — | WO | claimed |
| EP-0378318-A1 | Process for synthesis of FK-506 and tricarbonyl intermediates | MERCK & CO. INC. (US) | 1990-07-18 | — | — | EP | claimed |
| CN-122036718-A | ALK5 inhibitor and preparation method and application thereof | 安炎达医药技术(广州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-0405994-A2 | Synthetic process for FK-506 type macrolide intermediates | MERCK & CO. INC. (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0378318-A1 | Process for synthesis of FK-506 and tricarbonyl intermediates | MERCK & CO. INC. (US) | 1990-07-18 | — | — | EP | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | SMN1; SMN2 2462/4885ALDH1A1 457/4885PKM 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.